doi: 10.1021/jm0609622.
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist
Affiliations
- PMID: 17181143
- DOI: 10.1021/jm0609622
Item in Clipboard
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist
J Med Chem.
.
Abstract
Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity. Compound 4 displayed good oral bioavailability in rat and may be a potential therapeutic agent for the treatment of various inflammatory diseases.
Similar articles
-
Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.Bioorg Med Chem Lett. 2009 Mar 1;19(5):1431-3. doi: 10.1016/j.bmcl.2009.01.033. Epub 2009 Jan 15. Bioorg Med Chem Lett. 2009. PMID: 19196511
-
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.Bioorg Med Chem Lett. 2009 Aug 1;19(15):4446-9. doi: 10.1016/j.bmcl.2009.05.049. Epub 2009 May 18. Bioorg Med Chem Lett. 2009. PMID: 19525110
-
Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. doi: 10.1124/jpet.106.118927. Epub 2007 May 11. J Pharmacol Exp Ther. 2007. PMID: 17496166
-
Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Epub 2015 Aug 10. Pulm Pharmacol Ther. 2015. PMID: 26271598 Review.
-
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.Pharmacol Ther. 2006 Oct;112(1):139-49. doi: 10.1016/j.pharmthera.2006.04.002. Epub 2006 May 23. Pharmacol Ther. 2006. PMID: 16720046 Review.
Cited by
-
Discovery of 1,5-Dihydro-4H-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2.ACS Med Chem Lett. 2021 Apr 8;12(5):836-845. doi: 10.1021/acsmedchemlett.1c00113. eCollection 2021 May 13. ACS Med Chem Lett. 2021. PMID: 34055234 Free PMC article.
-
Emerging strategies for cancer immunoprevention.Oncogene. 2015 Dec 10;34(50):6029-39. doi: 10.1038/onc.2015.98. Epub 2015 Sep 14. Oncogene. 2015. PMID: 26364615 Free PMC article. Review.
-
NRAS destines tumor cells to the lungs.EMBO Mol Med. 2017 May;9(5):672-686. doi: 10.15252/emmm.201606978. EMBO Mol Med. 2017. PMID: 28341702 Free PMC article.
-
The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions.Curr Diab Rep. 2015 Oct;15(10):68. doi: 10.1007/s11892-015-0638-x. Curr Diab Rep. 2015. PMID: 26275440 Review.
-
Exploration of Pyrido[3,4-d]pyrimidines as Antagonists of the Human Chemokine Receptor CXCR2.Molecules. 2023 Feb 23;28(5):2099. doi: 10.3390/molecules28052099. Molecules. 2023. PMID: 36903345 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous
